Compare Monster Beverage Corp (MNST) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Twist Bioscience Corp — how do they compare? Monster Beverage Corp trades at $45.5 (market cap $89.20B), while Twist Bioscience Corp trades at $121.77 (market cap $7.72B). The key difference: Monster Beverage Corp is far larger — about 11.6× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Monster Beverage Corp nearer its low. Which is the better fit depends on your goals.
| MNST | TWST | |
|---|---|---|
Market Cap | $89.20B | $7.72B |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $124.88 |
52-Week Low | $30.86 | $24.16 |
Enterprise Value | $87.49B | $7.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $45.69, up 1.13% today. The stock shows strong fundamentals with Q2 2026 EPS of $0.60 beating estimates, driven by 20% revenue growth and a 23.08% net income margin. A 2-for-1 stock split occurred on August 11, 2026. However, technical indicators signal a bearish trend, with the current price below key resistance levels. Analyst consensus is bullish with a $51.14 price target, but high valuation ratios like a P/E of 42.16 pose risks.
Outlook: MNST's international expansion and earnings beats support growth, but stretched valuations and bearish technicals suggest near-term volatility. Investment opportunity lies in sustained profit margins, while risks include competitive pressures and premium pricing sensitivity.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
